Foresight Diagnostics is a cancer diagnostics company that develops ultra-sensitive ctDNA assays through the combination of precision genomics and bioinformatics. Our proprietary PhasED-Seq technology tracks patient- and tumor-specific phased variants to detect residual disease down to the parts per million, enabling early and accurate relapse detection at the end of treatment. Our MRD platform, Foresight CLARITY, is available across multiple indications, including lymphoma, lung, and breast cancer.